Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo targets Hard-to-Treat pancreatic tumors

NCT ID NCT05687123

Recruiting now Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether combining two targeted therapies—sunitinib malate and Lutathera—is safe for people with advanced pancreatic neuroendocrine tumors that have spread or cannot be removed. Sunitinib blocks signals that help tumors grow, while Lutathera delivers radiation directly to tumor cells. The study will enroll 24 participants to find the best dose and watch for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sunitinib malate and lutetium Lu 177 dotatate (Lutathera)
What this could lead to
If this combination proves safe and effective, it could offer a new treatment option for people with advanced pancreatic neuroendocrine tumors.
What could go wrong
This is a very early Phase I trial with only 24 participants, so the main goal is safety, not effectiveness. The combination may cause significant side effects or may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenoma, Islet Cell pancreatic neoplasm pancreatic neuroendocrine neoplasm pancreatic neuroendocrine tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PANCREATIC NEUROENDOCRINE TUMOR PANCREATIC NEOPLASM STAGE III PANCREATIC NEUROENDOCRINE TUMOR AJCC V8 STAGE IV PANCREATIC NEUROENDOCRINE TUMOR AJCC V8 UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMOR

Contacts and locations

Locations

  • City of Hope Comprehensive Cancer Center

    ACTIVE_NOT_RECRUITING

    Duarte, California, 91010, United States

  • Memorial Hospital East

    RECRUITING

    Shiloh, Illinois, 62269, United States

  • Siteman Cancer Center at Christian Hospital

    RECRUITING

    St Louis, Missouri, 63136, United States

    Contact Email: •••••@•••••

  • Siteman Cancer Center at Saint Peters Hospital

    RECRUITING

    City of Saint Peters, Missouri, 63376, United States

    Contact Email: •••••@•••••

  • Siteman Cancer Center at West County Hospital

    RECRUITING

    Creve Coeur, Missouri, 63141, United States

    Contact Email: •••••@•••••

  • Siteman Cancer Center-South County

    RECRUITING

    St Louis, Missouri, 63129, United States

    Contact Email: •••••@•••••

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    RECRUITING

    Orange, California, 92868, United States

    Contact Email: •••••@•••••

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    RECRUITING

    Irvine, California, 92612, United States

    Contact Email: •••••@•••••

  • University Health Network-Princess Margaret Hospital

    ACTIVE_NOT_RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.